AI Frenzy Blinds the Market: JPMorgan’s ‘Golden’ Picks Outside the AI Hype

As the artificial intelligence revolution captivates investors, JPMorgan analysts warn that the market’s sectors with the most "durable growth" potential are being overlooked amidst this technological storm. While chip and cloud computing stocks break records, it is highlighted that fundamental sectors like healthcare and life sciences remain in the shadow cast by the AI hype, harboring a tremendous opportunity area.

The Blind Spot Behind the AI Frenzy

While the majority of investors flock to AI players like Nvidia, it is emphasized that the market is becoming unbalanced. JPMorgan argues that this one-way street prevents the valuation of companies with stable revenue streams that are less affected by economic cycles. This situation is described as a serious risk factor for long-term portfolios, yet also seen as an opening door for value-oriented buyers.

The Demand for Health and Science Is Endless

In the bank's report, the companies highlighted as the strongest "picks" outside the tech realm are as follows:

■Eli Lilly: The pharmaceutical giant drawing attention with its leadership in obesity and diabetes treatments.

■AbbVie: Stands out with its strong patent portfolio in immunology and oncology.

■Danaher Corporation: Shown as a safe haven with its global dominance in life sciences and diagnostic tools.

While markets are currently living in AI dreams, the demand for real-world necessities like drugs and diagnostic tools never ceases. Adding giants like Eli Lilly and AbbVie to portfolios as cash flow kings, far from the volatility caused by the chip crisis, is not just diversification but a prime example of rational intelligence. We love technology, but let us not forget; human health is always the highest priority and the least competitive, most durable growth model.